Journal of Clinical Pathology · 2016 · 42 citations · 38 references
MedicineEndocrinologyOncologyBreast OncologyEndocrine OncologyMolecular OncologyBreast PathologyEndocrine Tumor PathologyEndocrine Tumor PrognosisHormonal Cancer TherapyBreast Cancer HistopathologyBreast Cancer PrognosisEstrogen Receptor StatusHistological TypingHormone Receptor - Positive Breast CancerProgesterone Receptor StatusProgesterone ReceptorsTissue Microarrays
AIMS: The presence of oestrogen and progesterone receptors (ER, PR) in breast carcinoma is an important prognostic indicator as well as a predictor of likely response to hormonal treatment. Current ambiguity surrounds ER-negative (-)/PR-positive (+) breast cancer (BC) as to whether this phenotype exists as a distinct entity. The independent predictive value of PR for treatment considerations is also in question, as some investigators believe ER status to be the single most important therapeutic predictive factor in BC. We undertook this study to determine the existence of ER(-)/PR(+) BC and the prognostic effect, if any, of this phenotype. METHODS: We investigated 267 archival documented ER(-)/PR(+) BCs diagnosed between January 1994 and July 2009. Histological slides were retrieved and reviewed. Tissue microarrays were constructed by selecting two 1 mm cores of tumour per case. Repeat immunohistochemistry was performed for confirmation of the ER(-)/PR(+) status. Clinicopathological parameters including age, ethnicity, tumour size, histological grade, histological subtype, associated ductal carcinoma in situ, lymphovascular invasion and lymph node status were evaluated. RESULTS: On repeat immunohistochemistry, 92 tumours were confirmed as ER(-)/PR(+) BCs. This phenotype accounted for 1.1% of all BC phenotypes and exhibited different clinicopathological features and survival outcome when compared with other phenotypes. ER(-)/PR(+) tumours showed a trend for an early recurrence and poorer overall survival as compared with the patients with ER(+)/PR(+) tumours and similar to ER(-)/PR(-) tumours. CONCLUSIONS: Our findings suggest that ER(-)/PR(+) BCs exist, although rare, with distinct pathological and clinical characteristics from patients with ER(+)/PR(+) BCs.
38
Molecular portraits of human breast tumours
Charles M. Perou, Thérese Sørlie, Michael B. Eisen et al. · Nature · 2000 · 16.3K citations
M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett et al. · Journal of Clinical Oncology · 2010 · 4.3K citations · Full text
Medicine, Cancer Biology, Oncology +14
Tissue microarrays for high-throughput molecular profiling of tumor specimens
Juha Kononen, Lukas Bubendorf, Anne Kallionimeni et al. · Nature Medicine · 1998 · 4.1K citations
Tamoxifen for early breast cancer: an overview of the randomised trials
The Lancet · 1998 · 4.1K citations
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text